Last reviewed 2026-04-20 · How we verify

Megrin (HEPRONICATE)

Phase 2 active Small molecule

Megrin (generic name: HEPRONICATE) is a hepronicate drug. It is currently in Phase 2 development.

Megrin works by interacting with a specific molecular target to produce a therapeutic effect.

Megrin (HEPRONICATE) is a small molecule drug in the hepronicate class, but specific details about its development, approval status, and commercial status are not available. As a hepronicate, it is likely used to treat a specific condition, but the exact target and indications are unknown. The safety profile and pharmacokinetic properties of Megrin are also not well-documented. Further research is needed to understand its clinical use and potential risks. As a result, Megrin is not a well-characterized drug.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	HEPRONICATE
Drug class	hepronicate
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Megrin has a key that fits into those locks. When Megrin binds to its target, it helps to regulate the activity of the cells, which can help to treat a particular condition. This is a simplified explanation of how Megrin works at a molecular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Megrin CI brief — competitive landscape report
Megrin updates RSS · CI watch RSS

Frequently asked questions about Megrin

What is Megrin?

Megrin (HEPRONICATE) is a hepronicate drug.

How does Megrin work?

Megrin works by interacting with a specific molecular target to produce a therapeutic effect.

What is the generic name of Megrin?

HEPRONICATE is the generic (nonproprietary) name of Megrin.

What drug class is Megrin in?

Megrin belongs to the hepronicate class. See all hepronicate drugs at /class/hepronicate.

What development phase is Megrin in?

Megrin is in Phase 2.

Drug class: All hepronicate drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing